EGFR and adenocarcinoma: Of note, a paired genomic analysis proposed, in a single center study, that an acquired genomic alteration in LKB1 through activation of the PI3K/AKT/mTOR pathway might favor the adenocarcinoma to squamous cell transformation after EGFR-TKIs [24].